NanoLogix Inc (NNLX)

[Omar8]

Yman,


If you look at these three releases from 2020 they are interesting, Faro is very positive and something I find interesting is they entered into a..... "Confidentiality Agreements with two diagnostic and financial groups for this purpose and are inviting additional interest.".........werent they not able to do that at that time because of that "matter" wasn't resolved ?



Oct. 28, 2020

Narrative of Some Issues Faced By NanoLogix Since May Announcement of Rapid COVID19 test

Issues are Resolved and NanoLogix Is Proceeding with Technology Development and Awaiting the Allowed Patent Issuance

Appreciation to Congressman Tim Ryan for his Interest and Assistance in Resolution

NanoLogix is presenting this narrative to illustrate the unusual and unanticipated challenges that were presented to the Company beginning immediately after our announcement of the invention and the initial results for a rapid viral detection test technology applicable to COVID-19 and other viruses.

Within a few days of our May 3rd announcement covering this news, we were reported by an unknown party or parties to FINRA, the FDA, and the SEC.

During the course of these events, and until their resolution, we did not believe we could approach investors for funding necessary for the further development of the technology. Nor could we seek development partners until this "Matter" was resolved. NanoLogix was delayed and blocked for approximately five months until the resolution of the "Matter" with no action recommended.


June 3, 2020

NanoLogix Seeks Development & Marketing Partner for Their Sub 1-Hour COVID-19 Detection Tests

HUBBARD, Ohio, June 3, 2020 /PRNewswire/ -- NanoLogix, Inc. (OTC: NNLX), an innovator in the rapid detection and identification of viruses and bacteria, is seeking a partner or partners for obtaining FDA Emergency Use Authorization, if required, and for development and marketing of their sub 1-hour COVID-19 Point of Care modified-ELISA detection test. This Rapid Viral Assay can also be configured for other viruses, such as, but not limited to, HIV, HPV, Hepatitis, MERS, and SARS-1. A Home-Test version of the COVID-19 test has the potential of 30-minute results using a nasopharyngeal swab or saliva samples.

CEO Bret Barnhizer stated: "NanoLogix does not possess the scale of production or marketing required for this essential test distribution for COVID-19. We cannot expand rapidly enough to meet the immediate need for testing. We have entered into Confidentiality Agreements with two diagnostic and financial groups in the last week for this purpose and are inviting additional interest."

Jonathan Faro, MD, PhD., Chief Medical Officer stated: "We are extremely excited over this technology development. It is a novel approach in diagnostics that provides a solution to the inherent problems with false positives and false negatives present in those tests currently being used in the war against COVID-19."


May 31, 2020

NanoLogix and COVID-19 Testing News

Realizing that many of our shareholders are from areas where they may not be aware of news coverage of NanoLogix developments, the Company is pleased to present the following links to articles written and interviews done during the month of May.

Warren Tribune:

https://www.tribtoday.com/news/local-news/2020/05/hubbard-based-nanologix-creates-rapid-covid-19-test/

Youngstown Vindicator:

https://www.vindy.com/opinion/brenda-j-linert/2020/05/all-roads-still-lead-to-the-mahoning-valley/

Youngstown Vindicator:

https://www.vindy.com/news/local-news/2020/05/fast-test-detects-variety-of-viruses/

Channel 27 (CBS) Youngstown:

Fox News 13 Tampa:

The Youngstown Vindicator is now published by the Warren Tribune, so while we link to one example, duplicate articles can be found for the same dates for both newspapers.


May 29, 2020

NanoLogix Rolls Out New Website With COVID-19 Testing Information

NanoLogix is pleased to announce their new website at www.nanologix.com. In visiting the website, please take note of the new PowerPoint titled: "Testing for COVID-19: Why current testing strategies don’t work" authored by Jonathan Faro, MD, PhD., and James Rogers, PhD., clearly presenting the reasons why the new NanoLogix COVID-19 detection technology is essential.

The Company is in the process of increasing its filled Petri plates product offerings with revised pricing on the Purchase Page so those pages are listed as under construction. That status will end in a few days and anyone currently needing to order can contact the Company directly. We continue to accept orders via email and phone.


May 18, 2020

NanoLogix Sub 1-Hour Covid-19 Detection Test Now Patent-Pending

Patent Application Filed Under New COVID-19 Prioritized Examination Pilot Program

NanoLogix is pleased to announce the filing of a patent application for use in the rapid testing for the Covid-19 virus. The application was filed under a new program instituted May 14th by the US Patent and Trademark Office. Now that Patent-Pending status has been obtained, we can reveal aspects of the technology that we were unable to mention in a prior update.

This Rapid Viral Assay is a modified ELISA technology that is not the same as our N-Assay modified ELISA.

While the initial focus for development was for the COVID-19 virus, it became obvious that the technology is not limited to one virus, but can be configured for many different viruses, such as HIV, HPV, Hepatitis, MERS, SARS-1 and others. As per the patent filing, the description is "Without Limitation".

An additional aspect of the test is that for the Home-Test configuration, we anticipate the potential of 30-minute results using a nasopharyngeal swab sample or saliva.

Jonathan Faro, MD, PhD., our Chief Medical Officer stated "We are extremely excited over this technology development, as it is a novel approach in diagnostics that provides a solution to the inherent problems with false positives and false negatives present in those tests currently being used in the war against COVID-19."

The US Patent Office program under which the filing was done can be accessed through the following link:

https://www.federalregister.gov/documents/2020/05/14/2020-10372/covid-19-prioritized-examination-pilot-program